<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Brown E</submitter><funding>University of Leeds</funding><funding>Medical Research Council</funding><funding>UK Research and Innovation</funding><pagination>e68404</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11449487</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13</volume><pubmed_abstract>&lt;i>Flaviviruses&lt;/i>, including &lt;i>Zika virus&lt;/i> (ZIKV), are a significant global health concern, yet no licensed antivirals exist to treat disease. The small membrane (M) protein plays well-defined roles during viral egress and remains within virion membranes following release and maturation. However, it is unclear whether M plays a functional role in this setting. Here, we show that M forms oligomeric membrane-permeabilising channels in vitro, with increased activity at acidic pH and sensitivity to the prototypic channel-blocker, rimantadine. Accordingly, rimantadine blocked an early stage of ZIKV cell culture infection. Structure-based channel models, comprising hexameric arrangements of two &lt;i>trans&lt;/i>-membrane domain protomers were shown to comprise more stable assemblages than other</pubmed_abstract><journal>eLife</journal><pubmed_title>Inhibitors of the small membrane (M) protein viroporin prevent Zika virus infection.</pubmed_title><pmcid>PMC11449487</pmcid><funding_grant_id>G0700124</funding_grant_id><funding_grant_id>Impact Acceleration Account ( IAA)</funding_grant_id><funding_grant_id>LIMR Studentship</funding_grant_id><funding_grant_id>MR/T016205/1</funding_grant_id><funding_grant_id>MC_UU_12014/8</funding_grant_id><funding_grant_id>Impact Acceleration Account (IAA)</funding_grant_id><funding_grant_id>MR/N017552/1</funding_grant_id><pubmed_authors>Lefteri DA</pubmed_authors><pubmed_authors>Kohl A</pubmed_authors><pubmed_authors>Moran A</pubmed_authors><pubmed_authors>Brown E</pubmed_authors><pubmed_authors>Beaumont H</pubmed_authors><pubmed_authors>Kalli AC</pubmed_authors><pubmed_authors>Maskell D</pubmed_authors><pubmed_authors>Thompson RF</pubmed_authors><pubmed_authors>McKimmie CS</pubmed_authors><pubmed_authors>Bentham MJ</pubmed_authors><pubmed_authors>Swinscoe G</pubmed_authors><pubmed_authors>Macdonald A</pubmed_authors><pubmed_authors>Griffin S</pubmed_authors><pubmed_authors>Singh R</pubmed_authors><pubmed_authors>Donald C</pubmed_authors><pubmed_authors>Ranson N</pubmed_authors><pubmed_authors>Foster R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Inhibitors of the small membrane (M) protein viroporin prevent Zika virus infection.</name><description>&lt;i>Flaviviruses&lt;/i>, including &lt;i>Zika virus&lt;/i> (ZIKV), are a significant global health concern, yet no licensed antivirals exist to treat disease. The small membrane (M) protein plays well-defined roles during viral egress and remains within virion membranes following release and maturation. However, it is unclear whether M plays a functional role in this setting. Here, we show that M forms oligomeric membrane-permeabilising channels in vitro, with increased activity at acidic pH and sensitivity to the prototypic channel-blocker, rimantadine. Accordingly, rimantadine blocked an early stage of ZIKV cell culture infection. Structure-based channel models, comprising hexameric arrangements of two &lt;i>trans&lt;/i>-membrane domain protomers were shown to comprise more stable assemblages than other</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Aug</publication><modification>2026-06-02T18:40:25.872Z</modification><creation>2025-04-06T22:28:46.92Z</creation></dates><accession>S-EPMC11449487</accession><cross_references><pubmed>39177307</pubmed><doi>10.7554/eLife.68404</doi></cross_references></HashMap>